Fast approaching the end of its patent life, Roche and Novartis’ Xolair is going out with a bang, picking up a new approval as the first and only drug therapy for people w
At the World Without Disease Summit next month, Infinant Health CEO Mike Johnson will discuss his company’s unique insights into the infant microbiome.
For the 32 million individuals in the US with food allergies, more research into symptoms, causes, and treatments has been long sought after, but historically underfunded.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh